Welcome to Quest PharmaTech Inc.

Quest PharmaTech is a publicly traded (QPT:TSXV), Canadian based pharmaceutical company developing products to improve the quality of life. The Company has an equity investment in OncoQuest Inc, which is developing antibody based immunotherapeutic products for cancer and which has recently entered into an asset transfer agreement with Korean based OncoQuest Pharmaceuticals, Inc. for the amount of US $300 Million. Quest has an ownership interest in Bioceltran which is focused on SP Technology™ for transdermal delivery of drugs and photosensitizers for pharmaceutical and cosmetic purposes.  Quest is also developing an antibody licensed from the University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications (OncoCare Therapeutics), and also mutant EGF licensed from Stanford University for dermatology and would healing applications.

Press releases 2022

September 28, 2022
Quest PharmaTech Announces Sale of Bioceltran Investment and Return of Photodynamic Therapy Technology License

April 19, 2022
Quest PharmaTech Provides Corporate Update

Press releases 2021

September 1, 2021
OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer

July 7, 2021
Quest PharmaTech Announces Results from AGM

June 1, 2021
Quest PharmaTech Announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists

March 26, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

February 2, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

January 5, 2021
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc. and OncoQuest Pharmaceuticals Inc.

Press releases 2020

November 9, 2020
Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company’s Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer

June 4, 2020
Quest Provides Corporate Update

May 29, 2020
Quest Provides Additional Information on OncoQuest Transaction and Announces Delay in Annual Filings

April 22, 2020
OncoQuest Signs a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer

March 24, 2020
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company’s Lead Investigational Drug in Frontline Ovarian Cancer

March 13, 2020
OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.

Press releases 2019

September 25, 2019
OncoQuest Receives “Notice of Allowance” for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients

January 29, 2019
Quest PharmaTech Announces Results from AGM

January 25, 2019
OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer

Press releases 2018

December 19, 2018
Quest PharmaTech Adopts Amendment to By-laws Requiring Advance Notice of Nomination of Directors

December 3, 2018
Quest PharmaTech Announces Adoption of Shareholder Rights Plan

November 28, 2018
Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.

July 20, 2018
Madenco Biosciences Announces Strategic Decision to Drop Consumer Health Products and Focus on Pharmaceutical Product Development

June 1, 2018
Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting

May 14, 2018
Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer

February 12, 2018
OncoQuest to Present at BIO CEO & Investor Conference

February 6, 2018
OncoQuest Completes US $6 Million Private Placement

January 3, 2018
Madenco Biosciences Announces Licensing Agreement for Patented EGF Wound Healing Technology